VKTX - Viking Therapeutics' Weight Loss Study Data Outperformed Novo Nordisk Eli Lilly Studies Analysts Say | Benzinga
Viking Therapeutics Inc (NASDAQ:VKTX) recently released top-line results from a successful Phase 2 weight loss trial.
Patients receiving VK2735 demonstrated statistically significant reductions in body weight compared with placebo.
The San Diego-based company also announced a capital raise of $350 million. Underwriters have an option to purchase up to an additional $52.5 million.
With the remarkable weight loss observed in Viking’s Phase 2 VK2735 trial, HC Wainwright and William Blair present a comparison with percent body weight changes from baseline at the 13-week mark in the VENTURE trial against Novo Nordisk A/S’s (NYSE:NVO) Phase 3 STEP-1 trial with Wegovy (semaglutide) and Eli Lilly And Co’s (NYSE:LLY) Phase 3 SURMOUNT-1 trial involving Zepbound (tirzepatide).
HC Wainwright says that VK2735 outperforms these two other studies.
When examining VENTURE against STEP 1, a ...